ASTCT Pharmacy SIG Journal Club Session
November 29, 2023
2-3 PM CDT

TARGET AUDIENCE
This session is intended for pharmacists and other members of the health care team who are involved in managing patients undergoing CAR T-cell therapy or hematopoietic stem cell transplant.

PROGRAM OVERVIEW
This webinar consists of two, 30-minute journal club presentations, which include 20 minutes for the presentation and 10 minutes for discussion and a Q&A session. In the November Journal Club session, Drs. Patel and Gash will present two articles related to:

a. Ciltacabtagene autoleucel or standard of care treatment in lenalidomide-refractory multiple myeloma, and
b. Post-transplant cyclophosphamide, abatacept, and a short course of tacrolimus (CAST) after peripheral blood haploidentical HSCT.

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

- Review the role of CAR T-cell therapy in relapsed/refractory multiple myeloma
- Describe the mechanism of action of ciltacabtagene autoleucel
- Evaluate the efficacy and safety of ciltacabtagene autoleucel compared to standard regimens in the management of relapsed/refractory multiple myeloma
- Review graft-versus-host disease (GVHD) prophylaxis regimens following haploidentical hematopoietic stem cell transplantation (HCT)
- Analyze the safety and efficacy of post-transplant cyclophosphamide (PTCy), abatacept, and a short course of tacrolimus (CAST) for GVHD prevention
- Discuss the utility of the CAST regimen for GVHD prevention after haploidentical HCT

FACULTY & ARTICLES

Shikha P. Patel, PharmD, BCPS
PGY-2 Pharmacy Resident
Mayo Clinic
Article: Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Kyle Gash, PharmD
PGY-2 Pharmacy Resident
Moffitt Cancer Center
Article: PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
Instructions for Participation and Requesting Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form. A score of at least 75% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.

Credit Fulfillment
- If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days.

ACCREDITED PROVIDER
This activity is jointly provided by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT).

In support of improving patient care, this activity has been planned and implemented by The France Foundation and American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CREDIT DESIGNATION
Pharmacists
This knowledge-based activity, UAN JA0007204-9999-23-041-L01-P, qualifies for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

All other healthcare professionals completing this course will be issued a statement of participation.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the American Society for Transplantation and Cellular Therapy (ASTCT) that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Disclosures
The individuals listed below disclosed the following relevant financial relationships:

<table>
<thead>
<tr>
<th>Name of Individual</th>
<th>Individual’s Role in Activity</th>
<th>Name of Commercial Entity</th>
<th>Nature of Relationship(s)</th>
<th>Mechanism(s) implemented to resolve conflict of interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley Smeaton, MHA</td>
<td>TFF Staff</td>
<td>No relevant financial disclosures</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Elizabeth Eubanks</td>
<td>Reviewer</td>
<td>1. Medexus Pharmaceuticals, Inc., Dedham Group</td>
<td>1. Non-CE Consulting</td>
<td>The following relationships were mitigated by: • Medexus Pharmaceuticals ended 5/25/22 • Dedham Group ended 3/24/23</td>
</tr>
<tr>
<td>Haedyn Smith</td>
<td>ASTCT Staff</td>
<td>No relevant financial disclosures</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Jamie Ziggas</td>
<td>ASTCT Reviewer</td>
<td>No relevant financial disclosures</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Kyle Gash, PharmD</td>
<td>Faculty</td>
<td>No relevant financial disclosures</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Olivia White</td>
<td>ASTCT Reviewer</td>
<td>No relevant financial disclosures</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Shikha Patel, PharmD, BCPS</td>
<td>Faculty</td>
<td>No relevant financial disclosures</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Timothy Porter</td>
<td>ASTCT Journal Club Coordinator</td>
<td>1. Medexus Pharmaceuticals, Inc.</td>
<td>1. Non-CE Consulting</td>
<td>The following relationship was mitigated by: • Medexus Pharmaceuticals ended in June 2022</td>
</tr>
</tbody>
</table>

DISCLOSURE OF UNLABELED USE
TFF and ASTCT require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the
most recent prescribing information.

**DISCLAIMER**
TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and ASTCT assume no liability for the information herein.

**CONTACT INFORMATION**
If you have questions about this CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.